Aaron Byrne

Senior Manager at BioMarin Pharmaceutical, Inc.

Aaron Byrne

Aaron Byrne

Senior Manager at BioMarin Pharmaceutical, Inc.

Overview
RelSci Relationships

328

Contact Data
Trying to get in touch with Aaron Byrne? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Aaron Byrne likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Rapidscan Pharma Solutions, Inc.

Relationship likelihood: Average

Medical Director-Medical Sciences at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Senior Medical Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Area Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Coordinator at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Project Coordinator at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Paths to Aaron Byrne
Potential Connections via
Relationship Science
You
Aaron Byrne
Senior Manager at BioMarin Pharmaceutical, Inc.
Career History
Senior Manager
Tenure Unconfirmed

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Other Affiliations

Aaron Byrne is affiliated with BioMarin Pharmaceutical, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Aaron Byrne. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Aaron Byrne's profile does not indicate a business or promotional relationship of any kind between RelSci and Aaron Byrne.